effect of Ayurvedic medicines in the treatment of ChronicAllergic Conjunctivitis
- Conditions
- Health Condition 1: null- Chronic Allergic ConjunctivitisHealth Condition 2: H104- Chronic conjunctivitis
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 55
1.Patients of either sex with age between 18
and 60 years.
2.Patients presenting with signs and symptoms
of Chronic Allergic Conjunctivitis having
history of seasonal or perennial allergic
conjunctivitis for at least 1 year on the
basis of following objective and subjective
parameters i.e.-Redness,Itching,Lacrimation,
Photophobia,FB Sensation,Burning
Sensation,Lid Swelling
3. Patients willing to participate and give
written informed consent to participate in
the study for 10 weeks including 2 weeks
without drug follow-up
1. Patients having associated marginal corneal
ulcer, Dacryocystitis, Trachoma, Kerato-
Conjunctivitis, infective conjunctivitis,
allergic to dyes and seborrhic Blepharitis,
dandruffs etc.
2. Patients positive for conjunctival smear and
culture to exclude any infective occurrence.
3. Patients with concurrent serious hepatic
disorder (defined as Aspartate Amino
Transferase (AST) and / or Alanine Amino
Transferase (ALT), Total Bilirubin, Alkaline
Phosphatase (ALP) > 2 times upper normal
limit.
4. Patients having serious Renal Dysfunction,
uncontrolled Pulmonary Dysfunction,
(asthmatic and COPD patients) or other
concurrent severe disease.
5. Patients with uncontrolled Diabetes Mellitus
(Blood Sugar Fasting > 250 mg/dl)
6. Patients with poorly controlled Hypertension
( > 160/100 mmHg).
7. Pregnant / lactating females.
8. Patients on steroids, oral contraceptives,
or estrogen replacement therapy.
9. Smokers/Alcoholics and/or drug abusers.
10. Patients suffering from major systemic
illness necessitating long term drug
treatment (Rheumatoid arthritis, Psycho-
Neuro - Endocrinal disorders, etc.).
11. H/o hypersensitivity to the trial drug or
any of its ingredients.
12. Patients who have completed participation
in any other clinical trial during the past
six months.
13. Any other condition which the Investigator
thinks may jeopardize the study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method â?¢Changes in VAS in subjective Symptoms e.g. <br/ ><br>Itching, Lacrimation, photophobia, FB sensation, <br/ ><br>Burning sensation and presence or absense of <br/ ><br>Lid swellingTimepoint: At baseline,14,28,42,56 and at the end of follow <br/ ><br>up after 10 weeks.
- Secondary Outcome Measures
Name Time Method Change in grading pattern of rednessTimepoint: At baseline,14,28,42,56 and at the end of follow <br/ ><br>up after 10 weeks.